27
Apr
Aiming to enable launch of its innovative nasal spray in 17 countries in the European Union, Glenmark Pharmaceuticals Limited is concluding the final phase of its marketing approval application process. Ryaltris, developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. Ryaltris will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK. Glenmark will commercialise Ryaltris on its own in select…
